Geodon

(Ziprasidone)

ApprovedSmall molecule

Ziprasidone is used to treat schizophrenia and bipolar disorder by helping to balance certain chemicals in the brain that affect mood and perception. It can help reduce symptoms like hallucinations, delusions, and mood swings.[2] Geodon is currently approved and in use across 12 indications[4].[1]

Geodon is one of 330 small molecule programs targeting Bipolar Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

329

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Bipolar DisorderCompleted

Mood DisorderApproved

Cardiovascular DiseaseApproved

Metabolic SyndromeActive, not recruiting

Depressive DisorderApproved

HyperglycemiaCompleted

Major Depressive DisorderCompleted

SchizophreniaCompleted

Diabetes MellitusCompleted

Generalized Anxiety DisorderCompleted

Bipolar DisorderApproved

Completed

Mood DisorderApproved

Approved

Cardiovascular DiseaseApproved

Approved

Metabolic SyndromeApproved

Active, not recruiting

Depressive DisorderApproved

Approved

HyperglycemiaPreclinical

Completed

Major Depressive DisorderApproved

Completed

SchizophreniaApproved

Completed

Diabetes MellitusApproved

Completed

Generalized Anxiety DisorderApproved

Completed

Showing 10 of 11 indications

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Geodon

Pfizer

Approved

20 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Schizophrenia

NCT03781115

Clinical

Trials by Indication[1]

Schizophrenia20 trials

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02600741·296 enrolled

Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00139737·344 enrolled

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00034801·378 enrolled

Show 17 more trials

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Completed·VVanda Pharmaceuticals·Phase 3·NCT00254202·593 enrolled

CATIE- Schizophrenia Trial

Completed·NNational Institute of Mental Health (NIMH)·Phase 4·NCT00014001·1,600 enrolled

Switching Medication to Treat Schizophrenia

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00044655·219 enrolled

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01006551·40 enrolled

Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00239109·112 enrolled

A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00649844·147 enrolled

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Completed·SSheba Medical Center·N/A·NCT00229385·45 enrolled

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00257192·284 enrolled

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00265382·221 enrolled

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Terminated·NNorthwestern University·Phase 3·NCT00288353·48 enrolled

IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00136994·160 enrolled

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00645515·240 enrolled

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

Completed·NNorthwell Health·Phase 4·NCT00330863·357 enrolled

A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

Completed·—·N/A·NCT02192723·550 enrolled

A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00645372·242 enrolled

Effectiveness of Ziprasidone for Patients With Schizophrenia

Completed·SSoonchunhyang University Hospital·Phase 4·NCT01198353·67 enrolled

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Active, not recruiting·UUniversity of Arizona·Phase 1·NCT03781115·24 enrolled

Psychosis9 trials

Efficacy and Safety With Ziprasidone in First-episode Psychosis

Completed·—·Phase 4·NCT01157559·27 enrolled

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00645320·75 enrolled

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00644800·89 enrolled

Show 6 more trials

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

Completed·FFundación Marques de Valdecilla·Phase 4·NCT02526030·203 enrolled

Ziprasidone in the Psychosis Prodrome

Completed·YYale University·Phase 2·NCT00635700·51 enrolled

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up

Completed·FFundación Marques de Valdecilla·Phase 4·NCT02534363·136 enrolled

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

Completed·FFundación Marques de Valdecilla·Phase 4·NCT02305823·203 enrolled

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00145444·100 enrolled

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

Completed·NNew York State Psychiatric Institute·Phase 3·NCT00421954·8 enrolled

Bipolar Disorder7 trials

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

Terminated·MMassachusetts General Hospital·Phase 4·NCT00374543·3 enrolled

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated·UUniversity of New Mexico··NCT02893371·1,037,352 enrolled

Ziprasidone in Pediatric Bipolar Disorder

Completed·—·Phase 4·NCT00622739·28 enrolled

Show 4 more trials

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

Completed·TThe University of Texas Health Science Center at San Antonio·N/A·NCT00538642·24 enrolled

Treatment and Outcome of Early Onset Bipolar Disorder

Completed·NNorthwell Health·Phase 4·NCT00048802·40 enrolled

Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT01293825·30 enrolled

Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

Completed·MMassachusetts General Hospital·Phase 4·NCT00181922·20 enrolled

Schizoaffective Disorder7 trials

A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00650429·28 enrolled

A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00645229·1 enrolled

Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00137020·294 enrolled

Show 4 more trials

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.··NCT00454883·379 enrolled

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

Completed·MManhattan Psychiatric Center·Phase 2/3·NCT00395031·57 enrolled

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00634348·256 enrolled

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00649064·46 enrolled

Bipolar I Disorder7 trials

Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00257166·238 enrolled

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00280566·584 enrolled

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT02075047·171 enrolled

Show 4 more trials

Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)

Withdrawn·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01117220

Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00265330·169 enrolled

Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)

Withdrawn·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01124877

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT03768726·23 enrolled

35 more indications

Antipsychotics6 trials

Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

Completed·UUniversity of Bergen·Phase 4·NCT00932529·226 enrolled

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Unknown status·SShanghai Mental Health Center·Phase 4·NCT04446234·350 enrolled

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

Completed·BBronx Psychiatric Center·Phase 4·NCT00458211·40 enrolled

Show 3 more trials

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Completed·SSolvay Pharmaceuticals·Phase 3·NCT00347425·286 enrolled

Energy Homeostasis Under Treatment With Atypical Antipsychotics

Completed·—·Phase 4·NCT00148564·40 enrolled

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed·TTechnical University of Munich·Phase 4·NCT02307396·21 enrolled

Major Depressive Disorder3 trials

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Completed·MMassachusetts General Hospital·Phase 2·NCT00633399·458 enrolled

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

Completed·MMassachusetts General Hospital·Phase 2·NCT00555997·120 enrolled

Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder

Completed·TTufts Medical Center·Phase 4·NCT01168674·49 enrolled

Agitation3 trials

Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

Completed·UUniversity of Sao Paulo·N/A·NCT01485692·120 enrolled

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

Completed·HHennepin Healthcare Research Institute··NCT03211897·737 enrolled

The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation

Unknown status·YYang Fude·Phase 4·NCT02935998·1,000 enrolled

Safety and Efficacy2 trials

A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.··NCT01053429·3,391 enrolled

Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness

Completed·MMedical College of Wisconsin·Phase 4·NCT00199940·20 enrolled

ESS2 trials

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00174447·43 enrolled

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

Completed·TTufts Medical Center·Phase 2·NCT00490542·73 enrolled

Depression2 trials

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

Completed·—·Phase 2/3·NCT00340379·72 enrolled

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00483548·298 enrolled

Treatment2 trials

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

Unknown status·SShanxi Medical University·Phase 1/2·NCT02650102·200 enrolled

Treatment of Schizophrenic Patients With Ziprasidone

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.··NCT00579670·450 enrolled

Relapse1 trial

Mozart Relapse Study

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00143351·75 enrolled

Cardiovascular1 trial

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Completed· Pfizer logo

Pfizer·Phase 4·NCT00418171·18,239 enrolled

Interaction1 trial

Gene-by-Stress Interactions in Intervention Studies Significance

Terminated·—·Phase 1·NCT03011645·7 enrolled

Borderline personality disorder1 trial

Ziprasidone in the Treatment of Borderline Personality Disorder

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT00635921·60 enrolled

Metabolism1 trial

Glucose and Lipid Metabolism on Antipsychotic Medication

Completed·WWashington University School of Medicine·N/A·NCT00515723·96 enrolled

Weight Gain1 trial

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

Terminated·NNorthwell Health·Phase 4·NCT01844700·14 enrolled

Prospective1 trial

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Completed·—·Phase 4·NCT00224315·24 enrolled

Major Depression1 trial

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

Completed·TThe Medical Research Network·Phase 4·NCT00237666·30 enrolled

Acceptability1 trial

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

Unknown status·GGuiyun Xu·Phase 4·NCT01893229·120 enrolled

Diabetes Mellitus1 trial

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

Completed·NNorth Suffolk Mental Health Association·Phase 4·NCT00351000·24 enrolled

Drug1 trial

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed·OOrganon and Co··NCT01498770·42 enrolled

Efficacy1 trial

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00406315·255 enrolled

Social Anxiety Disorder1 trial

Geodon for the Treatment of Refractory Social Anxiety Disorder

Completed·—·Phase 2·NCT00215150·51 enrolled

Autism1 trial

Ziprasidone in Children With Autism: A Pilot Study

Completed·—·Phase 2·NCT00208559·15 enrolled

Completed·MMedical University of Vienna·Phase 4·NCT01185743·16 enrolled

Generalized Anxiety Disorder1 trial

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

Completed·VVA Palo Alto Health Care System·Phase 4·NCT01172652·49 enrolled

Opioids1 trial

Reducing the Abuse Liability of Prescription Opioids

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04587115·15 enrolled

Efficacy and Safety1 trial

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00312494·680 enrolled

Cognitive impairment1 trial

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Completed· Astellas logo

Astellas·Phase 2·NCT03557931·233 enrolled

Metabolic Syndrome1 trial

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome

Completed·UUniversity of Malaya·Phase 4·NCT01714011·175 enrolled

Delirium1 trial

The MIND Study: Modifying the INcidence of Delirium

Completed·VVanderbilt University·Phase 2·NCT00096863·102 enrolled

Function1 trial

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

Completed·VVanderbilt University Medical Center·Phase 3·NCT01211522·566 enrolled

Post-Traumatic Stress Disorder1 trial

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

Completed·—·Phase 4·NCT00208208·80 enrolled

TED1 trial

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

Withdrawn·GGeorge Washington University·Phase 4·NCT00786318

Hyperglycemia1 trial

A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers

Completed·WWashington University School of Medicine·Preclinical·NCT00910988·46 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 5, 2001

GEODON

NDA NDA020825

May 25, 2001

GEODON

NDA NDA020825

May 25, 2001

GEODON

NDA NDA020825

Jun 7, 2001

GEODON

NDA NDA020825

Jan 22, 2002

GEODON

NDA NDA020825

Feb 15, 2002

GEODON

NDA NDA020825

Jun 21, 2002

GEODON

NDA NDA020919

Jun 21, 2002

GEODON

NDA NDA020919

Jun 25, 2002

GEODON

NDA NDA020825

Dec 23, 2003

GEODON

NDA NDA020825

Aug 13, 2004

GEODON

NDA NDA020919

Aug 13, 2004

GEODON

NDA NDA020825

Aug 19, 2004

GEODON

NDA NDA020825

Aug 17, 2005

GEODON

NDA NDA020919

Aug 17, 2005

GEODON

NDA NDA020825

Aug 17, 2005

GEODON

NDA NDA020825

Aug 17, 2005

GEODON

NDA NDA020919

Mar 29, 2006

GEODON

NDA NDA021483

Mar 2, 2007

GEODON

NDA NDA020825

Mar 2, 2007

GEODON

NDA NDA020919

May 24, 2007

GEODON

NDA NDA020919

May 24, 2007

GEODON

NDA NDA020825

Oct 2, 2007

GEODON

NDA NDA020919

Oct 2, 2007

GEODON

NDA NDA020825

May 16, 2008

GEODON

NDA NDA020919

May 16, 2008

GEODON

NDA NDA020825

Aug 14, 2008

GEODON

NDA NDA020919

Aug 14, 2008

GEODON

NDA NDA020825

Dec 19, 2008

GEODON

NDA NDA020919

Jul 19, 2009

GEODON

NDA NDA020825

Jul 19, 2009

GEODON

NDA NDA020919

Nov 12, 2009

GEODON

NDA NDA020825

Nov 20, 2009

GEODON

NDA NDA020825

Dec 1, 2010

GEODON

NDA NDA020919

Dec 1, 2010

GEODON

NDA NDA020825

Mar 1, 2013

GEODON

NDA NDA020825

Mar 1, 2013

GEODON

NDA NDA020919

Jul 3, 2013

GEODON

NDA NDA020825

Jul 3, 2013

GEODON

NDA NDA020919

Aug 13, 2013

GEODON

NDA NDA020919

Aug 13, 2013

GEODON

NDA NDA020825

Dec 17, 2013

GEODON

NDA NDA020825

Dec 17, 2013

GEODON

NDA NDA020919

Mar 28, 2014

GEODON

NDA NDA020919

Jun 9, 2014

GEODON

NDA NDA020919

Dec 10, 2014

GEODON

NDA NDA020825

Dec 10, 2014

GEODON

NDA NDA020919

Jun 17, 2015

GEODON

NDA NDA020825

Aug 20, 2015

GEODON

NDA NDA020825

Aug 20, 2015

GEODON

NDA NDA020919

Feb 23, 2017

GEODON

NDA NDA020825

Feb 23, 2017

GEODON

NDA NDA020919

Nov 5, 2018

GEODON

NDA NDA020919

Nov 5, 2018

GEODON

NDA NDA020825

Jan 23, 2020

GEODON

NDA NDA020919

Jan 23, 2020

GEODON

NDA NDA020825

Oct 29, 2020

GEODON

NDA NDA020919

Oct 29, 2020

GEODON

NDA NDA020825

May 18, 2021

GEODON

NDA NDA020825

May 18, 2021

GEODON

NDA NDA020919

Jan 28, 2022

GEODON

NDA NDA020825

Jan 22, 2025

GEODON

NDA NDA020825

Jan 22, 2025

GEODON

NDA NDA020919

Sources

References

[1]
ClinicalTrials.gov — 98 trial records for Ziprasidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Geodon drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ziprasidone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ziprasidone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020825). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin 2a (5-Ht2a) Receptor Antagonist; Dopamine D2 Receptor Antagonist; Serotonin 2c (5-Ht2c) Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Geodon

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Schizophrenia20 trials

Psychosis9 trials

Bipolar Disorder7 trials

Schizoaffective Disorder7 trials

Bipolar I Disorder7 trials

Antipsychotics6 trials

Major Depressive Disorder3 trials

Agitation3 trials

Safety and Efficacy2 trials

ESS2 trials

Depression2 trials

Treatment2 trials

Relapse1 trial

Cardiovascular1 trial

Interaction1 trial

Borderline personality disorder1 trial

Metabolism1 trial

Weight Gain1 trial

Prospective1 trial

Major Depression1 trial

Acceptability1 trial

Diabetes Mellitus1 trial

Drug1 trial

Efficacy1 trial

Social Anxiety Disorder1 trial

Autism1 trial

Tic Disorder1 trial

Tics1 trial

Gene Expression1 trial

Generalized Anxiety Disorder1 trial

Opioids1 trial

Efficacy and Safety1 trial

Cognitive impairment1 trial

Metabolic Syndrome1 trial

Delirium1 trial

Function1 trial

Post-Traumatic Stress Disorder1 trial

TED1 trial

Hyperglycemia1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News